Newer cancer drugs that enlist the body's immune system are improving the odds of survival, but competition between them is not reining in prices that can now top $250,000 a year. The drugs' success for patients is the result of big bets in cancer therapy made by big pharma. New drugs called checkpoint inhibitors work by releasing a molecular brake, allowing the immune system to recognize and attack cancer cells the same way it fights infections caused by bacteria or viruses. For cancers like melanoma, the treatments can mean long-term survival for around 20 percent of patients. Current checkpoint inhibitors each have a list price near $150,000 a year. A combination of drugs used for advanced or inoperable melanoma, has a cost of $256,000 a year for patients who respond to the treatment. The pharmaceutical industry holds that discussion of prescription drug prices has to take into account the major investment required for innovation and discovery of new lifesaving drugs. http://feeds.reuters.com/~r/reuters/topNews/~3/8zgJrpzhMlQ/us-usa-healthcare-cancer-costs-idUSKBN1750FU http://www.wochit.com This video was produced by YT Wochit Business using http://wochit.com
Pharmac chief executive Steffan Crausaz says the price of the melanoma drug Keytruda is one of the issues stopping the drug being publicly funded... but there are others. The Nation: Sat 9.30am/Sun 10am/Mon 11pm TV3 & Sat 7pm RadioLive. Or see us online at thenation.co.nz
Fuente:http://blogs.sciencemag.org/pipeline/archives/2017/05/25/an-approval-like-no-other En el estudio, publicado en la revista Science, se le dio seguimiento a 86 pacientes que padecían cáncer de páncreas, próstata, útero y en los huesos en estadio avanzado. Los pacientes fueron tratados con Pembrolizuma, también conocido como Keytruda. Los resultados fueron muy prometedores: en 66 pacientes los tumores se redujeron significativamente y en 18 de ellos desaparecieron por completo y no han vuelto a reproducirse. Todos los pacientes compartían una mutación genética que impedía que sus células repararan el ADN dañado. Pembrolizumab es un bloqueador de la proteína PD -1; es decir, se trata de un fármaco emergente de inmunoterapia que ayuda al sistema inmunitario a encontrar las células cancerosas y atacar los tumores.
The markets sold off a little more to start the week as tech stocks weighed on the overall market. The Dow 30 was lower by 16, the S&P 500 closed the day flat and the Nasdaq 100 closed down 17 on the day. Goldman Sachs (NYSE: GS) was your worst performer in the Dow as banks continue to selloff following earnings. The “FANG” stocks helped pull the Nasdaq 100 lower on the day, with Amazon (NASDAQ: AMZN), and Netflix (NASDAQ: NFLX) being the worst performers. The 10 year treasury note yield reached the 3% mark for the first time since 2014 today which further flattens out the yield curve. This has many concerned of a pending recession, and was a focus on financial media today. Merck (NYSE: MRK) shares were higher by 2.40% today, leading the Dow 30. Shares neared a three month high following a double upgrade from Goldman Sachs. The analyst upgraded the stock to Conviction buy thanks to the progress and success of their lung cancer drug, Keytruda. Goldman now has a price target of $73, up from $63 due to their assumptions that Keytruda will be a “$16 billion asset by 2025.” In other news, Alaska Air (NYSE: ALK) shares added 5.70% despite missing revenue numbers as overall profit came in higher than expected. Hasbro (NYSE: HAS) earnings came up short but investors bought the dip, closing shares higher by 4%. Halliburton (NYSE: HAL) announced mixed earnings but shares remained near the high end of the recent range. As for earnings, this will be the busiest week of earnings season with over 170 names in the S&P 500 reporting by the end of the week. Facebook (NYSE: FB), Amazon (NASDAQ: AMZN), and Alphabet (NASDAQ: GOOGL) are some of the names that will likely dominate this weeks, earnings headlines.
HHS Secretary Alex Azar on the Trump administration's efforts to reduce drug prices.
Experts report that there are new findings in immunotherapy for lung cancer.
Ongoing public scrutiny of US drug prices has begun to limit the pricing power pharmaceutical companies have enjoyed for decades, according to Goldman Sachs Research’s Jami Rubin—a trend she calls “The Drug Pricing Shakeout.” She discusses early signs of pricing restraint she’s seen in the industry, as well as what could be ahead from the Trump Administration. Learn more: http://link.gs.com/ZZfD
Five years ago Julie Randall was told she was going to die. No ifs, no buts. Doctors not only said she had melanoma, but that the cancer had spread throughout her body. They said it was incurable and she’d be lucky if she survived the next nine months. But instead of despairing, Julie did something incredible. She made a promise to her family that she wouldn’t die. Then she did something even more amazing. Through sheer determination – and with time quickly running out – she forced her way onto an experimental drug trial in the United States. There had only been space for 70, until Julie became patient 71. This, however, was just the beginning of Julie Randall’s inspiring battle for survival. Reporter: Allison Langdon Producer: Garry McNab
Dr. Sam Waksal, former CEO of ImClone Systems, on how the new trade deal between the U.S., Canada and Mexico will help protect biologic drugs from generic competition for a longer period of time.